Early decisions in oncology carry disproportionate weight. Long before markets are fully visible, teams determine patient focus, evidence priorities, and ambition for differentiation. These choices accumulate quickly, setting programmes, investments, and narratives in motion even as conditions remain in flux.
As time passes, flexibility narrows, often without teams recognising it until genuine differentiation is already out of reach. Options slip away quietly, without a clear moment of closure.
At the start of the year, we articulated the importance of setting a strategic “North Star” for oncology assets to establish alignment. The question that follows is more difficult: how do you choose the right course when the future you are planning for is still forming – and may do so in more ways than one?
Strategic momentum under partial visibility
Uncertainty has always been part of oncology. What has evolved is the degree to which initial judgement now influences downstream opportunity.
Pipelines are denser. Competitive readouts arrive sooner. Standards of care can shift within development timelines rather than between them. Biomarker-defined populations continue to reshape patient distributions, while access and reimbursement frameworks adjust more slowly. An asset’s eventual context can change markedly while its clinical programme is still being assembled.
Momentum increasingly solidifies because earlier judgements persist, embedded in plans that are already advancing.
Within this environment, familiar patterns emerge. Some organisations extend today’s paradigm forward, treating it as a stable reference point for decision-making. Others explore several future possibilities in parallel, building rich perspectives while deferring firm commitment.
Both approaches are understandable. Both begin to strain when underlying assumptions encounter developments that move faster than expected. The result is often strategy that reads as coherent on paper, yet proves harder to sustain in practice.
Re-centring thinking on real decision environments
A recurring feature of upstream strategy work is gradual drift away from the point where success is ultimately determined.
In oncology, prescribers integrate evidence, experience, access realities, operational constraints, and patient needs into everyday trade-offs. Treatment pathways are the product of these cumulative decisions. Strategic intent that becomes detached from this environment risks losing relevance, even when supported by rigorous analysis. Future Worlds thinking keeps direction anchored in these realities.
Each “world” reflects a consistent way in which oncology care could plausibly evolve over a given horizon, shaped by how patients are identified, how therapies are sequenced, and how clinicians evaluate available options.
This grounding brings future thinking closer to lived clinical judgement, rather than separating it from current limitations.
Translating uncertainty into decision contexts
The Future Worlds thinking framework narrows uncertainty into a small set of contexts that teams can engage with meaningfully.
It does not attempt to catalogue every possible scenario, nor to offer a broad or aspirational picture of the “future of care.” Instead, it focuses on a limited number of futures that would materially alter strategic judgement – recognisable enough to feel tangible, but distinct enough to expose tension in existing assumptions.
Each world represents a different configuration of care that could emerge over time. Trends across treatment paradigms, biomarkers, access dynamics, and clinical behaviour are considered together, with sufficient proximity to today’s landscape to retain credibility. Operating within this structure reframes the quality of early discussion.
Landscape insight begins to inform judgement. Attention shifts towards where opportunity could endure under forces outside a team’s control, and what would need to be true for an asset to justify long‑term investment.
Their value lies in how these futures sharpen judgement and enable better choices.
From understanding to sustained commitment
One of the most unrelenting challenges in oncology strategy is converting deep insight into confident direction. By examining how care might play out, teams can identify opportunity spaces that remain relevant across divergent futures. These may relate to specific patient segments, lines of therapy, biomarker-defined niches, or moments in the treatment journey where unmet need persists.
For example, a biomarker-defined population that appears commercially marginal today may represent an attractive niche in one future, while becoming saturated or deprioritised in another, fundamentally changing both evidence priorities and investment logic early on.
Assets can then be mapped deliberately into these spaces. Positioning sharpens. Evidence plans become more selective, favoured for their ability to support decisions across varying circumstances, rather than optimised for a single anticipated outcome. Direction gains resilience because it has been shaped with adaptability in mind.
At portfolio level, this approach is especially powerful. When various assets are viewed through the same future lenses, internal trade-offs surface sooner. Investment conversations become more grounded. Decisions are made with a shared understanding of where longer-term value is likely to concentrate.
The same discipline supports de-prioritisation. Optionality often feels prudent under uncertainty. In practice, maintaining too many open paths diffuses focus. Structured future thinking strengthens the rationale for both commitment and letting go.
Designing forward, then working back
As programmes progress, future worlds evolve alongside them. Positioning hypotheses are refined. Evidence choices grow more targeted. Strategic intent develops without losing coherence.
Oncology rarely affords the luxury of waiting. By the time conditions feel clearer, development paths are largely fixed, investment has been allocated, and scope for meaningful differentiation has diminished.
The organisations that succeed are not those that forecast most accurately, but those that prepare for multiple futures – and make early decisions that remain robust as those futures unfold.
Future Worlds thinking offers a way to do that, while choice is still available, and before strategy becomes constrained by decisions already in motion.
If you’re exploring how to navigate early oncology decisions or bring greater clarity to portfolio strategy, we would welcome a discussion on how the Future Worlds framework has been applied with clients to elevate the quality of launch preparation.
The Uptake Launch Excellence Report 2026
